XML 57 R35.htm IDEA: XBRL DOCUMENT v3.25.4
Other Balance Sheet Components (Tables)
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable
Accounts receivable, net, as of December 31, 2025 and 2024 consisted of the following (in millions):
December 31,
20252024
Accounts receivable$368 $698 
Less: Wholesalers chargebacks, discounts and fees
(181)(340)
Less: Allowance for doubtful accounts
(3)— 
Accounts receivable, net$184 $358 
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets, as of December 31, 2025 and 2024 consisted of the following (in millions):
December 31,
20252024
Prepaid services$169 $173 
Down payments and prepayments related to manufacturing and materials
61 106 
Interest receivable42 59 
Value added tax receivable37 45 
Prepaid income tax
33 28 
Collaboration receivable13 58 
Income tax receivable8 72 
Other current assets45 58 
Prepaid expenses and other current assets
$408 $599 
Schedule of Other Assets, Noncurrent
Other non-current assets, as of December 31, 2025 and 2024 consisted of the following (in millions):
December 31,
20252024
Income tax receivable, non-current
$161 $97 
Inventory, non-current(1)
114 150 
Down payments and prepayments, non-current
100 139 
Deferred tax assets
81 81 
Goodwill
52 52 
Finite-lived intangible asset
45 40 
Equity investments6 14 
Other46 21 
Other non-current assets$605 $594 
_______
(1)Consisted of raw materials with an anticipated consumption beyond one year.
Schedule of Accrued Liabilities
Accrued liabilities, as of December 31, 2025 and 2024 consisted of the following (in millions):
December 31,
20252024
Provisions related to product sales (Note 3)
$509 $370 
Compensation-related420 312 
Manufacturing140 109 
Development operations106 120 
Other external goods and services57 131 
Property, plant and equipment45 99 
Royalties31 46 
Raw materials30 41 
Commercial23 45 
Clinical trials20 94 
Loss on future firm purchase commitments(1)
5 60 
Accrued liabilities$1,386 $1,427 
______
(1)Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (Note 7).
Schedule of Other Current Liabilities
Other current liabilities, as of December 31, 2025 and 2024 consisted of the following (in millions):
December 31,
20252024
Estimated reimbursements to wholesalers and distributors$84 $103 
Research and development funding liability (Note 5)
43 58 
Lease liabilities - financing (Note 10)
25 23 
Lease liabilities - operating (Note 10)
17 14 
Other16 23 
Other current liabilities$185 $221 
Schedule of Other Noncurrent Liabilities
Other non-current liabilities, as of December 31, 2025 and 2024 consisted of the following (in millions):
December 31,
20252024
Tax liabilities
$249 $231 
Other
36 36 
Other non-current liabilities
$285 $267 
Schedule of Deferred Revenue
The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the year ended December 31, 2025 (in millions):
Returns, rebates and other fees
Balance at December 31, 2024$(370)
Provision related to sales made in current period(436)
Provision related to sales made in prior periods
(13)
Payments and returns related to sales made in current period 28 
Payments and returns related to sales made in prior periods282 
Balance at December 31, 2025$(509)
The following table summarizes the activities in deferred revenue during the year ended December 31, 2025 (in millions):
December 31, 2024AdditionsDeductionsDecember 31, 2025
Net product sales
$188 $108 $(189)$107 
Other revenue
23 212 (90)145 
Total deferred revenue$211 $320 $(279)$252